Status:
COMPLETED
Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.
Lead Sponsor:
Yonsei University
Conditions:
Neonatal Seizure
Eligibility:
All Genders
Up to 1 years
Phase:
NA
Brief Summary
The pharmacogenomic profiles of drug metabolizing enzymes play an important role in pharmacokinetics (PK) of drugs. Phenobarbital (PB), worldwidely used for neonatal seizure, is a drug that requires c...
Eligibility Criteria
Inclusion
- Infant treated by phenobarbital monotherapy, diagnosed neonatal seizure
- Infant taken the drug concentration one more time
- given the informed consent
Exclusion
- progressed CNS disorder
- severe systemic illness
- GOT/GPT level more than 2times of normal value,more than 3times elevation of BUN/creatinine level
- congenital hemolytic anemia
- genetic disorder
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT01224457
Start Date
May 1 2008
End Date
May 1 2010
Last Update
January 31 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.